Protein Misfolding Diseases and Neurodegeneration: From Experimental Approach to Clinical Therapy

RSSWEBINARDHPAMA

Add to Calendar Protein Misfolding Diseases and Neurodegeneration: From Experimental Approach to Clinical Therapy 10/5/2022 5:00:00 PM 10/5/2022 6:15:00 PM Asia/Riyadh For More Details: https://wcmq.cloud-cme.com/course/courseoverview?EID=2273 Description: The series will enable the audience to understand the mechanism of protein misfolding and amyloid formation behind the most common neurodegenerative diseases across the world and learn about the most recent advancements in their potential treatment modalities to promote a better understanding of the healthcare management options now and in the future. Livestreamed false MM/DD/YYYY


Date & Location
Occurs monthly on the 3rd Wednesday starting on 10/5/2022 at 5:00 PM
Wednesday, October 5, 2022, 5:00 PM - 6:15 PM, Livestreamed

Overview
The series will enable the audience to understand the mechanism of protein misfolding and amyloid formation behind the most common neurodegenerative diseases across the world and learn about the most recent advancements in their potential treatment modalities to promote a better understanding of the healthcare management options now and in the future.

Target Audience
Specialties - Allied Health Professionals, Educators, Nurses, Pharmacists, Physicians, Researchers, Students

Overall Learning Objective
  1. 1- Identify the risk factors and patterns of onset of neurodegenerative diseases.
  2. 2- Demonstrate an understanding of the mechanisms of the development of the most common neurodegenerative diseases
  3. 3- List the latest developments in the field of diagnosis and treatment of neurodegenerative diseases.
  4. 4- Recognize the emerged importance of artificial intelligence in neurodegenerative diseases diagnosis
  5. 5- Recognize the associations between physical activity, sleep and cognitive function in older adults

Registration

Registration / Session: 12 USD ( 44 QAR )

REGISTRATION WARNING

Registration for courses managed by Weill Cornell Medicine-Qatar (WCM-Q) can only be completed through WCM-Q's official registration portal. Attendee registrations made through any other sites cannot be honored. WCM-Q is not able to refund fees paid through unaffiliated registration sites, such as eMedEvents.com, MedConfWorld.com, EventEgg.com, and 10times.com.

Please report any unauthorized websites or solicitations for registrations to [email protected].

Changes or Cancellations

  • Name changes or substitutions are not permitted.
  • All cancellation and refund requests must be made in writing and submitted via email to [email protected].
  • For a full refund of the registration fee, the cancellation request must be received at least 7 days prior to the session. No refund will be offered for cancellation request thereafter.
  • We will attempt to process the refund within 30 days of receiving any cancellation request.
  • Weill Cornell Medicine-Qatar reserves the right to cancel the course. In the event of a cancellation, fee deposit will be returned, but we will not be responsible for any other expenses including restricted or non-refundable airfare or hotel deposits.

Accreditation

The below accreditation details apply to EACH session.

 


DHP 

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Ministry of Public Health's Department of Healthcare Professions.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health's Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 1.25 hours.


ACCME

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to adhere to Ministry of Public Health's Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias. 

Scientific Planning Committee: Ali Chaari, PhD, Phyllis Sui Muffuh Navti, Doctorate in Pharmacy Practice, Bruce MacRae, RTT, Troyd Tristan Esteban, BSN, Gholam Redha Adeli, MD, Slim Smaoui, MD, Pradipta Paul, have no relevant financial relationships to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.
 
Faculty: Ali Chaari, PhD, Colin Masters, MD, Vladimir Uversky, PhD, Gholam Redha Adeli, MD, have no relevant financial relationships to disclose and WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.
Leonidas Stefanis, MD, has disclosed the following relationships: Advisor - Abbvie, ITF Hellas and Biogen; Honoraria - Sanofi; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.
Hamid Sohrabi, PhD, has disclosed the following relationships: Grant or research support - Biogen and Alnylam; Executive - SmarT inds WA; Independent Contractor (included contracted research) - Alector; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.
Rayaz Ahmed Malik, MD, has disclosed the following relationships: Honoraria - Novo Nordisk, Lilly and Proctor and Gamble; Grant or research support - Proctor and Gamble; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.
Angelo Antonini, MD, has disclosed the following relationships: Advisor - Abbvie, BIAL and UCB; Honoraria - THERAVANCE and ZAMBON; Grant or research support - BIAL; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.

Michael Scholl, MD, has disclosed the following relationships: Membership on Advisory Committees or Review Panels, Board Membership, etc. - NovoNordisk and Roche; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.

 
 SPC and Faculty: Tiago Outeiro, PhD, has disclosed the following relationship: Consulting Fee - Bial Biotech; WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.

 

 Administrative Contact: Safia Rabia has no relevant financial relationships to disclose and WILL NOT BE DISCUSSING unlabeled/unapproved use of drugs or products.

 
ICR: Ali Chaari, PhD, has no relevant financials relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.
 
The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.